The breakthrough came on molecular biologist Christopher Garcia's birthday. For more than 20 years, his team and others around the world had been chasing an elusive quarry—the 3D structure of a ...

Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist ...

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...

The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive ...

In a meta-analysis, topical Janus kinase (JAK) inhibitors demonstrated promising but non-significant results for vitiligo, with patients administered JAK inhibitors having a higher likelihood of ...

Switching to a second-line Janus kinase (JAK) inhibitor resulted in steroid-free clinical remission in about half of the patients with active ulcerative colitis (UC) after induction; compared with ...

Although treatment options for atopic dermatitis (AD) and alopecia areata (AA) exist, some patients experience inadequate response or intolerable adverse effects (AEs) that often negatively impact ...

Inflammatory cytokines play a major role in the pathogenesis of immune-mediated chronic inflammatory diseases. Cytokines are rarely produced alone and play their role in a complex network with others.

More than two decades of effort went into a project that has now revealed the structure of a crucial signaling molecule, opening the door to new and better drugs for some cancers. For more than 20 ...